Novel Mitophagy Inducer Alleviates Lupus Nephritis by Reducing Myeloid Cell Activation and Autoantigen Presentation.

Huijing Wang,Mingdi Shen,Yanhong Ma,Lan,Xue Jiang,Xufeng Cen,Gangqiang Guo,Qin Zhou,Mengmeng Yuan,Jianghua Chen,Hongguang Xia,Liang Xiao,Fei Han

DOI: https://doi.org/10.1016/j.kint.2023.12.017

IF: 19.6

2024-01-01

Kidney International

Abstract:Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE), but its mechanism of onset remains unclear. Since impaired mitophagy has been implicated in multiple organs in SLE, we hypothesized that mitophagy dysfunction is critical in the development of LN and that pharmacologically targeting mitophagy would ameliorate this disease. Therefore, lupus-prone MRL/MpJ- Fas lpr (MRL/lpr) and NZBWF1/J mice were treated with a novel mitophagy inducer, UMI-77, during their onset of LN. This treatment effectively mitigated kidney in flammation and damage as assessed by histology and flow cytometry. Furthermore, dendritic cell (DC) -T-cell coculture assay indicated that UMI-77 treatment attenuated DC function that would drive T-cell proliferation but did not directly in fluence the potent T-cell proliferation in lupus mice. UMI-77 also restored mitochondrial function and attenuated proin flammatory phenotypes in lupus DCs. Adoptive transfer of DCs from MRL/lpr mice augmented serum antidsDNA IgG, urine protein and T-cell in filtration of the kidney in MRL/MpJ mice, which could be prevented by either treating lupus donors in vivo or lupus DCs directly with UMI-77. UMI-77 also restored mitochondrial function in myeloid cells from patients with LN in vitro as evidenced by increased ATP levels. Thus, enhancing mitophagy in SLE restrains autoimmunity and limits kidney in flammation for LN development. Hence, our findings suggest targeting mitophagy as a tangible pathway to treat LN.